Drug intelligence / Profile preview

AVID-448

Development stage
Preclinical
Lead developer
AdCure Bio
Modality
Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration
Intravenous
01

Overview

AVID-448 is an engineered oncolytic adenovirus being developed by AdCure Bio for the treatment of solid tumors, including non-small cell lung cancer (NSCLC). It is designed as a sequential systemic therapeutic intended for intravenous administration, utilizing AdCure's proprietary platform to facilitate tumor-cell infection and lysis while overcoming the delivery challenges associated with traditional intratumoral oncolytic therapies. The virus is engineered to selectively infect, replicate within, and lyse tumor cells, potentially triggering a systemic anti-tumor immune response. As of 2024, the program is in the preclinical discovery and refinement stage.

02

Targets

FX-HSPG (Coagulation factor X and hepatocyte heparan sulfate proteoglycans)CXADR (Coxsackievirus and adenovirus receptor)PRR (Pattern recognition receptors)LAMA1 (Laminin subunit alpha-1)αVβ3 (Integrin αVβ3)

Beyond the preview

Go deeper on AVID-448.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVID-448.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call